We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Amorsa Therapeutics has announced a research, option and license agreement with Janssen Pharmaceuticals to develop and commercialise a novel small molecule drug candidate for treatment-resistant depression based on Amorsa’s proprietary ketamine analog tec